TITLE

Association of Busulfan and Cyclophosphamide Conditioning with Sleep Disorders after Hematopoietic Stem Cell Transplantation

AUTHOR(S)
Faulhaber, Gustavo A. M.; Furlanetto, Tania W.; Astigarraga, Claudia C.; Filho, Humberto Luiz Moser; Paludo, Angela Paula; Silla, Lucia M. R.
PUB. DATE
October 2010
SOURCE
Acta Haematologica;Oct2010, Vol. 124 Issue 2, p125
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
New indications and conditioning regimens for hematopoietic stem cell transplantation (HSCT) have emerged in the last 10 years. Previous studies have shown the association of HSCT with late effects such as sleep disorders. The aim of this study was to determine the prevalence and factors associated with sleep disorders following HSCT in a population considering these new trends. Sixty-one individuals 1-10 years after allogeneic HSCT were surveyed using the DSM-IV-TR criteria for sleep disorders. Factors related to conditioning and graft-versus-host disease were collected from medical records. A prevalence of sleep disorders of 26.2% was found. Busulfan-cyclophosphamide conditioning was an independent risk factor in a multivariate analysis (relative risk, RR: 3.74, 95% CI: 1.1-12.6; p = 0.03), which also included sex (RR: 2.37, 95% CI: 1.0-5.7; p = 0.05) and age (RR: 1.03, 95% CI: 0.99-1.07; p = 0.11). Sleep disorders were frequent following HSCT. Patients who were treated with busulfan-cyclophosphamide had a higher risk of developing this complication. Female sex was also possibly a risk factor. Copyright © 2010 S. Karger AG, Basel
ACCESSION #
54289549

 

Related Articles

  • Cyclophosphamide.  // Reactions Weekly;03/23/2013, Issue 1445, p17 

    The article focuses on a retrospective study, which identified the development of large pericardial effusion (LPE) with cardiac tamponade in two haematopoietic stem cell transplant (HSCT) recipients during treatment with high-dose cyclophosphamide.

  • Pharmacogenetics of Gemtuzumab-Associated Hepatic Sinusoidal Occlusion Syndrome after Hematopoietic Stem Cell Transplant. Aplenc, Richard; Vachani, Anil; Han, Peggy; Glatfelter, Wendy; Sievers, Eric L. // Acta Haematologica;Dec2003, Vol. 110 Issue 4, p207 

    Presents a study that investigated the pharmacogenetics of Gemtuzumab-associated hepatic sinusoidal occlusion syndrome (SOS) after hematopoietic stem cell transplant (HSCT). Variable risk of SOS development in patients exposed to gemtuzumab after HSCT; Analysis of reactive oxygen species...

  • Angioedema in patients treated with sirolimus and ACE inhibitor post hematopoietic SCT. Jung, M; Ranpura, V N; Dunbar, C E; Tisdale, J F; Fitzhugh, C D; Hsieh, M M // Bone Marrow Transplantation;Nov2014, Vol. 49 Issue 11, p1448 

    A letter to the editor is presented which discusses two cases of angioedema in patients treated with sirolimus and ACE inhibitors following hematopoietic stem cell transplantation (SCT).

  • Sirolimus.  // Reactions Weekly;9/12/2009, Issue 1269, p31 

    The article describes the case of a 44-year-old patient who underwent haematopoietic stem cell transplantation and developed sirolimus-induced proteinuria, 14 months after transplantation. The medical history of the patient is presented. It notes the dosage of the drug taken by the patient. The...

  • Treosulfan-based preparative regimens for allo-HSCT in childhood hematological malignancies: a retrospective study on behalf of the EBMT pediatric diseases working party. Wachowiak, J; Sykora, K-W; Cornish, J; Chybicka, A; Kowalczyk, J R; Gorczyńska, E; Choma, M; Grund, G; Peters, C // Bone Marrow Transplantation;Dec2011, Vol. 46 Issue 12, p1510 

    This retrospective analysis evaluated 51 children (0.7-17 years; median eight) with high-risk or advanced hematological malignancies, including 18 (35%) patients undergoing second/third hematopoietic SCT (allo-HSCT), not eligible for standard myeloablative regimens and transplanted from matched...

  • Retraction to: Allogeneic hematopoietic stem cell transplantation for acquired aplastic anemia using cyclophosphamide and antithymocyte globulin: a single center experience. Ladeb, S; Abdelkefi, A; Torjman, L; Ben Neji, H; Lakhal, A; Kaabi, H; Ben Hamed, L; Ennigrou, S; Hmida, S; Ben Othman, T; Ben Abdeladhim, A // Bone Marrow Transplantation;Mar2014, Vol. 49 Issue 3, p468 

    A retraction to the article "Allogeneic hematopoietic stem cell transplantation for acquired aplastic anemia using cyclophosphamide and antithymocyte globulin: a single center experience" that was published in the July 27, 2009 issue is presented.

  • Bortezomib-based induction for transplant ineligible AL amyloidosis and feasibility of later transplantation. Cornell, R F; Zhong, X; Arce-Lara, C; Atallah, E; Blust, L; Drobyski, W R; Fenske, T S; Pasquini, M C; Rizzo, J D; Saber, W; Hari, P N // Bone Marrow Transplantation;Jul2015, Vol. 50 Issue 7, p914 

    Recent studies support the use of bortezomib-based therapies in light chain amyloidosis (AL). We performed a retrospective analysis of the safety, efficacy and long-term survival (median follow-up 3 years) after bortezomib-based treatment in 28 consecutive patients with de novo AL deemed...

  • Population pharmacokinetics of cyclophosphamide in patients with thalassemia major undergoing HSCT. Balasubramanian, P; Desire, S; Panetta, J C; Lakshmi, K M; Mathews, V; George, B; Viswabandya, A; Chandy, M; Krishnamoorthy, R; Srivastava, A // Bone Marrow Transplantation;Sep2012, Vol. 47 Issue 9, p1178 

    CY in combination with BU is a widely used conditioning regimen for haematopoietic SCT (HSCT). The aim of this study was to evaluate the pharmacokinetics (PK) of CY and its major metabolite 4-hydroxyCY (HCY) in patients with thalassemia undergoing HSCT. A total of 55 patients received BU (16...

  • HY Immune Tolerance Is Common in Women without Male Offspring. Dierselhuis, Miranda P.; Jankowska-Gan, Ewa; Blokland, Els; Pool, Jos; Burlingham, William J.; van Halteren, Astrid G. S.; Goulmy, Els // PLoS ONE;Mar2014, Vol. 9 Issue 3, p1 

    Background: Sex difference is an established risk factor for hematopoietic stem cell transplantation (HSCT)-related complications like graft versus host disease (GVHD). CD8pos cytotoxic T cells specific for Y chromosome-encoded minor Histocompatibility antigens (HY) play an important role...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics